Vitamin C promotes ACE2 degradation and protects against SARS‐CoV‐2 infection
- 6 March 2023
- journal article
- research article
- Published by Springer Nature in EMBO Reports
- Vol. 24 (4) , e56374
Abstract
ACE2 is a major receptor for cellular entry of SARS-CoV-2. Despite advances in targeting ACE2 to inhibit SARS-CoV-2 binding, strategies to flexibly and sufficiently reduce ACE2 levels for the prevention of SARS-CoV-2 infection have not been explored. Here, we reveal vitamin C (VitC) administration as a potent strategy to prevent SARS-CoV-2 infection. VitC reduces ACE2 protein levels in a dose-dependent manner, while even a partial reduction in ACE2 levels can greatly inhibit SARS-CoV-2 infection. Further studies reveal that USP50 is a crucial regulator of ACE2 levels. VitC blocks the USP50-ACE2 interaction, thus promoting K48-linked polyubiquitination of ACE2 at Lys788 and subsequent degradation of ACE2 without affecting its transcriptional expression. Importantly, VitC administration reduces host ACE2 levels and greatly blocks SARS-CoV-2 infection in mice. This study reveals that ACE2 protein levels are down-regulated by an essential nutrient, VitC, thereby enhancing protection against infection of SARS-CoV-2 and its variants.Keywords
Funding Information
- National Natural Science Foundation of China (31970846)
- National Natural Science Foundation of China (32100568)
- National Key Research and Development Program of China (2018YFC1705505)
- National Key Research and Development Program of China (2018YFC1705500)
- China Postdoctoral Science Foundation (2021M692351)
- Project of Science and Technology of Suzhou (SKY2022108)
- Project of Natural Science Research in Colleges and Universities of Jiangsu Province (20KJB310008)
- Foundation for Young Scholars of Jiangsu Province (BK20200864)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
This publication has 45 references indexed in Scilit:
- Screening of DUB activity and specificity by MALDI-TOF mass spectrometryNature Communications, 2014
- Regulation of Vitamin C Homeostasis during DeficiencyNutrients, 2013
- Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancerCancer Chemotherapy and Pharmacology, 2013
- Angiotensin-converting enzyme 2 in lung diseasesCurrent Opinion in Pharmacology, 2006
- Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With DiabetesAmerican Journal of Kidney Diseases, 2005
- Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissuesProceedings of the National Academy of Sciences, 2005
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance.Proceedings of the National Academy of Sciences, 1996
- Male–female differences in fertility and blood pressure in ACE-deficient miceNature, 1995